Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

LSD shows promise for anxiety in new clinical trial

NCT ID NCT05407064

Symptom relief Sponsor: Definium Therapeutics US, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 study tested four different doses of MM120 (a form of LSD) against a placebo in 198 people with generalized anxiety disorder. The goal was to see which dose best reduces anxiety symptoms over 4 to 8 weeks. Participants took a single dose and were monitored for safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MM120 (LSD D-Tartrate)
What this could lead to
If successful, this could point toward a new treatment option for generalized anxiety disorder using a controlled dose of LSD.
What could go wrong
This is an early Phase 2 study with only 198 participants. The results may not apply to everyone, and LSD can cause intense psychological effects and risks like anxiety or confusion during the session.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

198 people

The number who actually took part.

Started

Aug 2022

Finished

Nov 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 74 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Bodyweight of ≥ 50 kg * Body mass index \[BMI\] ≥ 18 to ≤ 38 mg/kg2 * Diagnosis of DSM-5 generalized anxiety disorder * Acceptable overall medical condition to be safely enrolled into and to complete the study * Ability to swallow capsules * Ability to provide informed consent Exclusion Criteria: * Women of childbearing potential (WOCBP) (i.e., physiologically capable of becoming pregnant) who are unwilling or unable to use a highly effective method of contraception for the duration of the study, OR Men physiologically capable of fathering a child who are sexually active with WOCBP but are unwilling or unable to use barrier contraception (e.g., condom with or without spermicidal cream or jelly) for the duration of the study * Women who are currently pregnant or breastfeeding or plan to become pregnant or breastfeed during the study * Men who plan to donate sperm during the study * Prior history (lifetime diagnosis) with a lifetime diagnosis of schizophrenia spectrum, or other psychotic disorders or bipolar disorder * Has a significant risk of suicide attempt based upon medical history or has active suicidal ideation * Unwillingness or inability to discontinue prohibited concomitant medications, supplements or other therapeutics (prescription or over-the-counter)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety, generalized are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

generalized anxiety disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety, generalized

Contacts and locations

Locations

  • Adams Clinical

    Watertown, Massachusetts, 02472, United States

  • BioBehavioral Research of Austin

    Austin, Texas, 78759, United States

  • CNS Healthcare - Orlando

    Orlando, Florida, 32801, United States

  • Cedar Clinical Research

    Draper, Utah, 84020, United States

  • Cedar Clinical Research - Murray

    Murray, Utah, 84107, United States

  • GMI - Princeton Medical Institute

    Princeton, New Jersey, 08540, United States

  • Great Lakes Clinical Trials

    Chicago, Illinois, 60640, United States

  • Hassman Research Institute

    Berlin, New Jersey, 08009, United States

  • Irvine Center for Clinical Research

    Irvine, California, 92614, United States

  • Kadima Neuropsychiatry Institute

    La Jolla, California, 92037, United States

  • Lutheran Hospital - Cleveland Clinic

    Cleveland, Ohio, 44113, United States

  • Mountain View Clinical Research

    Denver, Colorado, 80209, United States

  • Pacific Neuroscience Institute

    Santa Monica, California, 90404, United States

  • Preferred Research Partners

    Little Rock, Arkansas, 72211, United States

  • SISU

    Springfield, Massachusetts, 01103, United States

  • Segal Trials

    Lauderhill, Florida, 33319, United States

  • Sunstone Therapies

    Rockville, Maryland, 20850, United States

  • University of Texas Health Houston

    Houston, Texas, 77054, United States

  • Uptown Research

    Chicago, Illinois, 60640, United States

  • Wholeness Center

    Fort Collins, Colorado, 80525, United States

  • Woodstock Research Center

    Woodstock, Vermont, 05091, United States

  • iResearch Atlanta

    Decatur, Georgia, 30030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.